SINGAPORE, Nov 6 (Bernama-BUSINESS WIRE) — Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced the establishment of its co-headquarters in Singapore, marking a major milestone in the company’s global expansion and deepening its commitment to advancing eye health worldwide. Eyexora’s seed financing was led by ClavystBio, a global life sciences investor based in Singapore, and its initial programs have been in-licensed from the Singapore Eye Research Institute (SERI).
The new Singapore headquarters will serve as a gateway to Eyexora’s growing activities across the Asia-Pacific region, supporting clinical development, research collaborations, and regional partnerships. This expansion further strengthens Eyexora’s collaboration with the Singapore Eye Research Institute (SERI), a long-standing partner in ophthalmic innovation.